Nom du produit:2-Chloro-4-[3-iodo-1-(1-methylethyl)-1H-pyrazol-4-yl]pyrimidine
IUPAC Name:2-chloro-4-[3-iodo-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidine
- CAS:1269440-58-5
- Formule moléculaire:C10H10ClIN4
- Pureté:95%+
- Numéro de catalogue:CM330056
- Poids moléculaire:348.57
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1269440-58-5
- Formule moléculaire:C10H10ClIN4
- Point de fusion:-
- Code SMILES:CC(N1N=C(I)C(C2=NC(Cl)=NC=C2)=C1)C
- Densité:
- Numéro de catalogue:CM330056
- Poids moléculaire:348.57
- Point d'ébullition:
- N° Mdl:
- Stockage:2-8°C, sealed storage, away from moisture and light
Category Infos
- Pyrazoles
- Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
- Pyrazone
- Custom pyrazone for customers from all over the world are our main business.
- Pyrimidines
- Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Column Infos
- Encorafenib plus Binimetinib
- U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.